Guggenheim analyst Seamus Fernandez raised the firm’s price target on Eli Lilly to $670 from $620 and keeps a Buy rating on the shares ahead of the company announcing Q3 results on Thursday, November 2. While Trulicity supply constraints are expected to continue impacting outside the U.S. results, “at the end of the day, all that matters is Mounjaro sales and supply updates,” the analyst tells investors in a preview note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on LLY:
- Johnson & Johnson (NYSE:JNJ) Predicts Short-Term Decline for Obesity Drugs
- Fly Insider: Biohaven, BJ’s Wholesale Club among weeks’ notable insider trades
- Eli Lilly (NYSE:LLY) Rises after Impressive Drug Results
- Inspire Medical initiated with a Market Perform at Leerink
- Merck (NYSE:MRK) Urges UK Government to Support Pharma